In Vitro interaction between cefixime and amoxicillin-clavulanate against extended-spectrum-beta-lactamase-producing Escherichia coli causing urinary tract infection

Journal of Clinical Microbiology

Volumn 50, Issue 7, 2012, Pages 2540-2541

  Bingen, Edouard ^a   Bidet, Philippe ^a   Birgy, André ^b   Sobral, Elsa ^b   Mariani, Patricia ^a   Cohen, Robert ^c  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b HÔPITAL ROBERT DEBRÉ   (France)

^c CENTRE HOSPITALIER INTERCOMMUNAL DE CRÉTEIL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; CEFIXIME; EXTENDED SPECTRUM BETA LACTAMASE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIAL GENE; BACTERIAL STRAIN; BACTERIUM CULTURE; BACTERIUM ISOLATE; COMBINATION CHEMOTHERAPY; CTX M GENE; DISK DIFFUSION; DRUG POTENTIATION; EPSILOMETER TEST; ESBL GENE; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTION; HUMAN; IN VITRO STUDY; LETTER; MINIMUM INHIBITORY CONCENTRATION; MULTIPLEX POLYMERASE CHAIN REACTION; NONHUMAN; OXA 1 GENE; PRIORITY JOURNAL; SHV 12 GENE; TEM 1 GENE; TEM 52 GENE; URINARY TRACT INFECTION;

ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; CEPHALOSPORINS; CLAVULANIC ACID; ENTEROBACTERIACEAE; ENZYME INHIBITORS; HUMANS;

EID: 84862742969     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.00526-12     Document Type: Letter

References (12)

1. Balke C, et al. 2006. Evaluation of the E test for the assessment of synergy of antibiotic combinations against multiresistant Pseudomonas aeruginosa isolates from cystic fibrosis patients. Eur. J. Clin. Microbiol. Infect. Dis. 25:25-30.
2. Bocquet N, et al. 2012. Randomized trial of oral versus sequential IV/oral antibiotic for acute pyelonephritis in children. Pediatrics 129(2):e269-75. doi:10.1542/peds.2011-0814.
3. Bolstrom A, Ardvison S, Ericson M, Karlsonn A. 1989. New in vitro models for studying antibiotic combination using predefined antibiotics gradient, abstr 011. Program and abstracts of the 16th International Congress of Chemotherapy, Jerusalem, Israel.
4. Campbell JD, Lewis JS, II, McElmeel ML, Fulcher LC, Jorgensen JH. 2012. Detection of favorable oral cephalosporin-clavulanate interactions by in vitro disk approximation susceptibility testing of ESBL-producing members of the Enterobacteriaceae. J. Clin. Microbiol. 50:1023-1026.
5. Clinical and Laboratory Standards Institute. 2011. Performance standards for antimicrobial susceptibility testing, 20th informational supplement. M100-S21, vol 31, no. 1. Clinical and Laboratory Standards Institute, Wayne, PA.
6. Dallenne C, Da Costa A, Decre D, Favier C, Arlet G. 2010. Development of a set of multiplex PCR assays for the detection of genes encoding important beta-lactamases in Enterobacteriaceae. J. Antimicrob. Chemother. 65:490-495.
7. Drieux L, Brossier F, Sougakoff W, Jarlier V. 2008. Phenotypic detection of extended-spectrum beta-lactamase production in Enterobacteriaceae: review and bench guide. Clin. Microbiol. Infect. 14:90-103.
8. European Committee on Antimicrobial Susceptibility Testing (EUCAST). 2008. Expert rules. European Committee on Antimicrobial Susceptibility Testing, Växjö, Sweden. http://www.eucast.org/clinical-breakpoints/.
9. Guay DR. 2000. Pharmacodynamics and pharmacokinetics of cefdinir, an oral extended spectrum cephalosporin. Pediatr. Infect. Dis. J. 19(12 Suppl):S141-S146.
10. Hoberman A, et al. 1999. Oral versus initial intravenous therapy for urinary tract infections in young febrile children. Pediatrics 104(1 Pt 1): 79-86.
11. Klepser ME, et al. 1995. Clinical pharmacokinetics of newer cephalosporins. Clin. Pharmacokinet. 28(5):361-384.
12. Manno G, et al. 2003. Use of the E test to assess synergy of antibiotic combinations against isolates of Burkholderia cepacia-complex from patients with cystic fibrosis. Eur. J. Clin. Microbiol. Infect. Dis. 22:28-34.